Michael Barbella, Managing Editor01.27.21
The U.S. Food and Drug Administration has granted 510(k) clearance to MedSkin Solutions' MatriDerm product portfolio.
"We are pleased with receiving 510(k) clearance for our MatriDerm products. This significant milestone represents our commitment at MedSkin Solutions Dr. Suwelack in bringing innovation and differentiated technologies to healthcare professionals and patients around the world," said Diana Ferro, president and CEO of MedSkin Solutions Dr. Suwelack AG.
Composed of bovine collagen fibers and bovine elastin, MatriDerm is a single-use 3D acellular dermal matrix used to manage full thickness and partial wounds. The technology is supported by more than 150 peer-reviewed published articles and currently sold worldwide, having treated over 300,000 patients.
"Like we have done across Europe, the Middle East, Asia, and Latin America our focus will be educating and supporting healthcare professionals and our partners as we look to commercialize MatriDerm in the largest medical device market globally," said Jason Gugliuzza, vice president, Med Care Division.
MedSkin Solutions Dr. Suwelack AG is a Germany-based expert in biotech solutions for tissue regeneration and skin health. Its technological core competence is our proprietary Advanced CryoSafe method that allows the company to maintain and refine the response of bioactive materials. Its science-based solutions create effective and easy-to-use treatments that deliver added value and serve equally patients and physicians.
"We are pleased with receiving 510(k) clearance for our MatriDerm products. This significant milestone represents our commitment at MedSkin Solutions Dr. Suwelack in bringing innovation and differentiated technologies to healthcare professionals and patients around the world," said Diana Ferro, president and CEO of MedSkin Solutions Dr. Suwelack AG.
Composed of bovine collagen fibers and bovine elastin, MatriDerm is a single-use 3D acellular dermal matrix used to manage full thickness and partial wounds. The technology is supported by more than 150 peer-reviewed published articles and currently sold worldwide, having treated over 300,000 patients.
"Like we have done across Europe, the Middle East, Asia, and Latin America our focus will be educating and supporting healthcare professionals and our partners as we look to commercialize MatriDerm in the largest medical device market globally," said Jason Gugliuzza, vice president, Med Care Division.
MedSkin Solutions Dr. Suwelack AG is a Germany-based expert in biotech solutions for tissue regeneration and skin health. Its technological core competence is our proprietary Advanced CryoSafe method that allows the company to maintain and refine the response of bioactive materials. Its science-based solutions create effective and easy-to-use treatments that deliver added value and serve equally patients and physicians.
